Meeting
2018 Gastrointestinal Cancers Symposium
A phase 2 study of s-1 plus leucovorin in patients with untreated advanced cholangiocarcinoma (CCA).
Authors
Suebpong Tanasanvimon
King Chulalongkorn Memorial Hospital, Bangkok, Thailand
Suebpong Tanasanvimon , Teerapat Ungtrakul , Nattaya Poovorawan , Napa Parinyanitikul , Chanida Vinayanuwattikun , Siyamol Mingmalairak , Sutima Luangdilok , Wisut Lamlertthon , Virote Sriuranpong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
TCTR20160313001
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 467)
DOI
10.1200/JCO.2018.36.4_suppl.467
Abstract #
467
Poster Bd #
M14
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase II study of olaparib and durvalumab in patients with IDH-mutated cholangiocarcinoma.
First Author: Erica S. Tsang
Poster
2021 Gastrointestinal Cancers Symposium
Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study.
First Author: Mitesh J. Borad
Poster
2020 Gastrointestinal Cancers Symposium
Phase II study of copanlisib in combination with gemcitabine and cisplatin in advanced cholangiocarcinoma.
First Author: Elaine Tan
Poster
2018 ASCO Annual Meeting
Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced cholangiocarcinoma: The AIO-NIFE-trial, an open label, randomized, multicenter phase II trial.
First Author: Thomas Jens Ettrich